By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Naurex Inc. 

1801 Maple Avenue
Suite 4300
Evanston  Illinois  60201  U.S.A.
Phone: 317-250-3276 Fax: n/a



Start Up

Company News
Naurex Spinout Aptinyx Banks $65 Million Series A to Advance Therapies for Neurological Disorders 5/10/2016 6:30:54 AM
After Allergan (AGN) Acquisition, Naurex Spins Out New Brain Research Company, Aptinyx 9/16/2015 5:51:46 AM
Allergan (AGN) Successfully Completes Naurex Acquisition 8/31/2015 6:34:11 AM
Allergan (AGN) Coughs Up $560 Million Cash for Naurex 7/27/2015 5:50:59 AM
Naurex Inc. To Present Clinical Data For NRX-1074 At 2015 American Society Of Clinical Psychopharmacology Annual Meeting 6/22/2015 12:42:38 PM
Naurex Inc. To Present Preclinical And Clinical Data For NRX-1074 And Rapastinel At Upcoming Scientific Meetings 5/12/2015 10:23:11 AM
Naurex Inc. To Present At 22nd Annual BioCentury Future Leaders In The Biotech Industry Conference 3/16/2015 9:30:58 AM
Naurex Inc.'s First Orally Active Molecule, NRX-1074, Demonstrates Statistically Significant Improvement In Depression Scores Within 24 Hours In Phase 2 Study For Major Depressive Disorder 1/27/2015 7:28:28 AM
Naurex Inc. To Present At 33rd Annual J.P. Morgan Healthcare Conference 12/19/2014 9:46:09 AM
Naurex Inc.'s GLYX-13 Demonstrates Robust, Sustained Antidepressant Effects And Excellent Tolerability In Phase 2b Study 12/10/2014 7:41:02 AM